Multi-omics joint analysis revealed the metabolic profile of retroperitoneal liposarcoma

Retroperitoneal liposarcoma(RLPS)is the main subtype of retroperitoneal soft sarcoma(RSTS)and has a poor prognosis and few treatment options,except for surgery.The proteomic and metabolic profiles of RLPS have remained unclear.The aim of our study was to reveal the metabolic profile of RLPS.Here,we performed proteomic analysis(n=10),metabolomic analysis(n=51),and lipidomic analysis(n=50)of retroperitoneal dedifferentiated liposarcoma(RDDLPS)and retroperitoneal well-differentiated liposarcoma(RWDLPS)tissue and paired adjacent adipose tissue obtained during surgery.Data analysis mainly revealed that glycolysis,purine metabolism,pyrimidine metabolism and phospholipid formation were upregulated in both RDDLPS and RWDLPS tissue compared with the adjacent adipose tissue,whereas the tricarboxylic acid(TCA)cycle,lipid absorption and synthesis,fatty acid degradation and biosynthesis,as well as glycine,serine,and threonine metabolism were downregulated.Of particular importance,the glycolytic inhibitor 2-deoxy-D-glucose and pentose phosphate pathway(PPP)inhibitor RRX-001 significantly promoted the antitumor effects of the MDM2 inhibitor RG7112 and CDK4 inhibitor abemaciclib.Our study not only describes the metabolic profiles of RDDLPS and RWDLPS,but also offers potential therapeutic targets and strategies for RLPS.

Overexpression of ASPH protein predicts poor outcomes in retroperitoneal liposarcoma patients

To the Editor:Liposarcoma is a common subtype of retroperitoneal sarcoma.Due to the complicated anatomical heterogeneity of retroperitoneal liposarcoma(RPLS),it compresses and invades adjacent important organs,and massive bleeding frequently occurs during surgery.Therefore,a combined visceral resection is required,which means that RPLS surgery has greater difficulty and a lower complete resection rate compared to surgeries for other solid tumors.Although in our previous studies we found that intraperitoneal thermoperfusion chemotherapy including cisplatin may improve the prognosis of patients with RPLS,[1]surgery is the most effective treatment for RPLS,and adjuvant therapies have shown almost ineffective.There is a paucity of research focusing specifically on molecular mechanisms underlying RPLS pathogenesis.Consequently,no diagnostic biomarkers,druggable targets,or prognostic factors are available for RPLS.

Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy:A 10-year real-world evidence

Objective:A prospective randomized control study investigated the feasibility and efficacy of adjuvant radiotherapy on patients with central hepatocellular carcinoma(HCC)after narrow-margin hepatectomy(<1 cm).This study presents an updated 10-year real-world evidence to further characterize the role of adjuvant radiotherapy.Methods:Patients with central HCC after narrow-margin hepatectomy(<1 cm)were prospectively assigned to adjuvant radiotherapy group and control group.Patients'outcome,adverse events,long-term recurrence and survival rates were investigated.Results:The 1-,5-,and 10-year recurrence-free survival(RFS)rates were 81.0%,43.9%,and 38.7%,respectively in adjuvant radiotherapy group and 71.7%,35.8%,and 24.2%,respectively in control group(log-rank test,P=0.09).The 1-,5-,and 10-year overall survival(OS)rates were 96.6%,54.7%,and 42.8%,respectively in adjuvant radiotherapy group and 90.2%,55.1%,and 30.0%,respectively in control group(log-rank test,P=0.20).The 1-,5-,and 10-year RFS rates for patients with small HCC(≤5 cm)were 91.1%,51.6%,and 48.4%,respectively in adjuvant radiotherapy group and 80.0%,36.6%,and 26.6%,respectively in control group(log-rank test,P=0.03).Landmark analysis demonstrated that patients with small HCC in adjuvant radiotherapy group had a significantly improved OS in second five years after treatment in comparison to patients in control group(log-rank test,P=0.05).Conclusions:Our updated results showed a sustained clinical benefit on reducing recurrence,improving longterm survival for small central HCC by adjuvant radiotherapy after narrow-margin hepatectomy.Long-term survival data also indicated that hepatectomy is an optimal treatment for selected patients with central HCC.

Establishment of an orthotopic perirenal space xenograft mousemodel of retroperitoneal sarcoma

Dear Editor,Soft tissue sarcomas are a heterogeneous group of rare malignancies with mesenchymal origin that can arise at any anatomic site.They account for almost 1.5% of all malignancies in humans,with an increased incidence in young adults[1,2].The retroperitoneum is the primary site of 15%-20% of soft tissue sarcomas[3,4].

Effects of cisplatin in combination with hyperthermia on biological characteristics of retroperitoneal liposarcoma

Pathologically,retroperitoneal liposarcoma(RPLS)is a group of malignant tumors,which originates from adipose tissue in retroperitoneal space,accounting for almost 70%of all retroperitoneal tumors.RPLS has no optimal treatment.Surgical resection(R_(0)/R_(1))is the most effective therapy;however,recurrence rate is very high.Grossly incomplete surgical resection(R_(2))is an important risk factor for early recurrence of RPLS.

Can aspirin use reduce the risk of pancreatic cancer:an updated systematic review and meta-analysis

Background:Chemoprevention effect of aspirin for pancreatic cancer(PC)remains unclear.Here we performed an updated systematic review and meta-analysis to investigate the real association between aspirin consumption and risk of PC.Methods:PubMed,Web of Science,EMBASE and the Cochrane Database were systematic searched to identify the potential studies.Odds ratio(ORs)with 95%confidence intervals(CIs)were applied to assess the strength of associations.Results:Thirteen studies and approximately 28,440 participants were included.Aspirin significantly reduced the incidence of PC(OR,0.82;95%CI,0.73-0.93)in case-control studies.However,the overall results did not reveal an obvious association(OR,0.92;95%CI,0.74-1.16).Both low-dose(OR=0.86)and high-dose(OR=0.80)aspirin intake showed prevention effect.In addition,low frequency(OR,0.87;95%CI,0.73-1.05)and high frequency(OR,0.84;95%CI,0.69-1.03)seemed to be equally associated with decreased risk for PC.Aspirin consumption longer than 10 years use seems to have better effect(OR,0.73;95%CI,0.51-1.04)than shorter aspirin use(OR,0.94;95%CI,0.77-1.15).Conclusions:Our study indicated that aspirin use might be associated with decreased risk of PC,especially at high doses.But we still need to be cautious when interpreting the results.

Chinese expert consensus on standardized treatment for presacral cysts

Presacral cysts are cystic or cyst–solid lesions between the sacrum and rectum,almost involving adjacent pelvic floorstructures including sacrococcygeal fascia,rectum,and anal sphincter.Presacral cysts are usually benign,currently believed to arise from aberrant embryogenesis.Presacral cysts are clinically rare and the true incidence is unknown.Surgical resection remains the major treatment for presacral cysts.Unless the cysts are completely resected,recurrence is unavoidable.Recurrent cysts or hard-to-heal sinuses in the sacrococcyx cause patients extreme pain.However,the current knowledge of presacral cysts is insufficient.They are occasionally confused with other diseases such as ovarian cysts and perianal abscesses.Moreover,lack of the correct surgical concept and skills leads to palliative treatment for complex presacral cysts and serious complications such as impairing the function of the anal sphincter or important blood vessels and nerves.The consensus summarizes the opinions and experiences of multidisciplinary experts in presacral cysts and aims to provide clinicians with a more defined concept of the treatment,standardize the surgical approach,and improve the efficacy of presacral cysts.